

Supporting Information

Synthesis of 2-Substituted Pyrimidines and Benzoxazoles via a Visible-Light-Driven Organocatalytic Aerobic Oxidation: Enhancement of Reaction Rate and Selectivity by a Base

Lin Wang,^a Zhi-Gang Ma,^a Xiao-Jing Wei,^a Qing-Yuan Meng,^b Deng-Tao Yang,^a Shao-Fu Du,^a Zi-Fei Chen,^a Li-Zhu Wu*^b and Qiang Liu*^a

^a State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, P. R. China. E-mail: liuqiang@lzu.edu.cn

^b Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, the Chinese Academy of Sciences, Beijing 100190, P. R. China. E-mail: lzwu@mail.ipc.ac.cn.

Table of Contents for Supporting Information

1. General Information.....	- 3 -
1.1 Solvents and Reagents	- 3 -
1.2 NMR and Mass Spectrometry & Chromatography	- 3 -
1.3 Electrochemistry	- 3 -
1.4 Electron spin resonance	- 3 -
1.5 Lash Flash photolysis	- 3 -
2. Preparation of starting materials	- 4 -
2.1 General procedure for the preparation precursor of compounds 1a-1u with the Biginelli three-component-coupling reaction	- 4 -
2.2 General procedure for the preparation of compounds 1a-1u with methylation reaction	- 4 -
2.3 General procedure for the preparation precursor of compounds 1l	- 5 -
2.4 General procedure for the preparation compounds 1l.....	- 5 -
2.5 General procedure for the one-pot preparation of compounds 1v-1x.....	- 5 -
2.6 General procedure for the synthesis of phenolic imines	- 6 -
3. General procedure for Photoredox Synthesis of 2-Substituted Pyrimidines.	- 6 -
4. General procedure for Photoredox Synthesis of 2-Substituted Benzoxazoles.....	- 7 -
5. Gram scale dehydrogenative oxidation reaction under ambient sunlight.....	- 7 -
6. The electrochemistry of DHPMs 1a.	- 8 -
7. Optimization of photocatalytic aerobic preparation of 2-phenylbenzoxazole	- 8 -
8. Study The Role of DBU by Transient Absorption Difference Spectra.	- 9 -
9. Characterization Data of the 2-Substituted dihydropyrimidines.	- 10 -
10. Characterization Data of the 2-Substituted Pyrimidines.....	- 16 -
11. Characterization Data of the 2-Substituted Benzoxazoles.....	- 22 -
12. REFERENCES	- 32 -
13. NMR SPECTRA.....	- 33 -
13.1 NMR Spectra Of 2-Substituted Dihydropyrimidines 1a-1x.....	- 33 -
13.2 NMR Spectra Of 2-Substituted Pyrimidines 2a-2x.....	- 57 -
13.3 NMR Spectra Of 2-Substituted Benzoxazoles 4a-5m.....	- 81 -

1. General Information:

1.1 Solvents and Reagents: Materials were obtained from commercial suppliers or prepared according to standard procedures unless otherwise noted. Solvents were dried using standard methods and distilled before use. PhCF₃ was dried over 4 Å molecular sieves and stored over under argon. All reactions were carried out in glassware opened to the air unless specified.

1.2 NMR and Mass Spectrometry & Chromatography: ¹H and ¹³C NMR spectra were recorded on Bruker AM-400 MHz instruments in CDCl₃ with TMS as internal standard. The chemical shifts (δ) are reported in ppm and coupling constants (J) in Hz. Chemical shifts are reported in parts per million (δ) relative to CDCl₃ (7.27 ppm) for ¹H NMR data and CDCl₃ (77.0 ppm) for ¹³C NMR data. Multiplicities are indicated, s (singlet), brs (broad singlet), d (doublet) , t (triplet), q (quartet), dd (double doublets), m (multiplet). Mass spectra were obtained on Bruker ESQ6K4 and TRACE DSQ. High resolution mass spectra and were performed on Bruker Daltonics APEXII 47e Specifications. Column chromatography was performed with silica gel (200-300 meshes). Thin layer chromatography (TLC) was visualized using UV light.


1.3 Electrochemistry: Electrochemical investigation was studied on a Princeton Applied Research Potentionstat-gravanostat model 283. Voltammograms were obtained using a standard three electrode cell under argon at room temperature with a glassy carbon working electrode and a platinum wire auxiliary electrode. A Ag/AgNO₃ (0.01 mmol.L-1) reference electrode was used and the supporting electrolyte solution was 0.1 M n-Et₄NBF₄, and potentials are reported relative to the Fc/Fc⁺ couple as 0.00 V. Between each scan the glassy carbon electrode was removed and polished using a 0.05 μm polycrystalline diamond suspension and rinsed with both acetone and deionized water to remove any adsorbed material.

1.4 Electron spin resonance: ESR spectra were recorded at room temperature using a Bruker ESP-300E spectrometer at 9.8 GHz, X-band with 100 Hz field modulation. TBA-eosinY, DHPMs **1a** and 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) or 2,2,6,6-tetramethylpiperidine (TEMP) in air-saturated methanol/water (10:1 v/v) was stirred in the dark , then the solution was injected into the quartz capillary. The samples were illuminated directly in the cavity of the ESR spectrometer with a Nd:YAG laser (532 nm, 5-6 ns pulse width, 10 Hz repetition frequency, 10 mJ pulse energy) for 10 s before measurement.

1.5 Lash Flash photolysis : The transient absorption spectroscopy was recorded on Edinburgh LP 920 at room temperature. A mixture of methanol/water (10:1 v/v) solution was degassed with nitrogen for 30 min before measurement. Excitation was provided using Nd:YAG laser (4th harmonic or OPO) at 532 nm and the detector was a xenon lamp on the Edinburgh LP 920 apparatus.


2. Preparation of starting materials.

2.1 General procedure for the preparation precursor of compounds 1a-1u with the Biginelli three-component-coupling reaction.¹




A round bottom flask was charged with ethanol (10 mL), appropriate aldehyde (20 mmol, 1.0 equiv), ethyl acetoacetate (20 mmol, 1.0 equiv), and urea (30 mmol, 1.5 equiv). To the mixture was added $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (1.863 g, 5 mmol, 0.1 equiv) and the batch was heated under reflux. The reaction was finished within 2-3 h (monitored by TLC until the conversion of aldehyde was completed). The mixture was cooled to room temperature and poured onto crushed ice (60 g) in the beaker. The product was stirred for 10min and then isolated by filtration. The wet cake was washed twice with cold water and once with ethanol (10 mL). Then the cake was recrystallized with ethanol (60 mL) and dried under reduced pressure at 40 °C overnight. Dihydropyrimidinone was obtained as a white solid.

2.2: General procedure for the preparation of compounds 1a-1u with methylation reaction.²




A flame-dried round-bottomed flask charged with a suitable magnetic stir bar, potassium carbonate (1.0 g, 7.25 mmol) and methyl iodide (220 μL , 3.5 mmol) was added into the suspension of 4-substituted-3,4-dihydropyrimidin-2(1H)-thione (3 mmol) in acetone (15 mL) under N_2 atmosphere. The reaction was stirred for overnight at room temperature (the reaction flask was wrapped in aluminium foil) and was diluted with EtOAc. The reaction system was filtered and the filtrate was washed with water and brine, dried with MgSO_4 and the solvent removed *in vacuo*. The crude residue was purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{acetone} = 20:1$) to afford the desired 4-substituted-1,4-dihydropyrimidine.

2.3: General procedure for the preparation precursor of compounds **1l**.³




In a 10 mL round bottomed flask equipped with a magnetic stirrer was placed with ethyl isobutyrylacetate (2.11 g, 13.34 mmol), 4-fluorobenzaldehyde (1.613 g, 13.30 mmol), isopropanol (1.0 ml), piperidine (72 μ L) and glacial acetic acid (42 μ L). The reaction mixture was stirred at room temperature under nitrogen for 22 h. The solvent was removed under reduced pressure. The residue was dissolved with methylene chloride (5 mL) and washed with sat. NaHCO_3 (3 \times 10 mL) and dried over anhydrous MgSO_4 . Removal of MgSO_4 and solvent afforded ethyl 2-(4-fluorobenzylidene)-4-methyl-3-oxopentanoate (3.19 g) in 95% yield as a mixture of cis/trans-isomers which was used in the subsequent step without further purification.

2.4: General procedure for the preparation compounds **1l**.⁴



The mixture of a solution of 4.468 g of compound ethyl 2-(4-fluorobenzylidene)-4-methyl-3-oxopentanoate in 6.5 mL of HMPA and 2.824 g of S-methylisothiourrea hydrogen sulfate was stirred at 100 °C for 22 h. The reaction mixture was extracted with Et_2O , and washed successively with sat. NaHCO_3 and water. The organic layer was dried, and the solvent was distilled away. The obtained residue was purified by flash chromatography (PE \rightarrow PE/ EtOAc = 100:1) to yield the corresponding **1l** as a pale yellow oil.

2.5: General procedure for the one-pot preparation of compounds **1v-1x**.⁵




A round bottom flask was charged with a mixture of O-methylisourea hydrogensulfate (1.48 g, 12 mmol), ethyl 3-oxobutanoate (1.30 g, 1.28 mL, 11.0 mmol), the appropriate aldehyde (10

mmol), NaHCO₃ (3.36g, 40 mmol) and DMF (20 mL) was heated at 70 °C for 3-4 h. After cooling, the mixture was diluted with brine (30 mL) and extracted with ether (2 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), dried over MgSO₄ and concentrated under reduced pressure. The residue was chromatographed on alumina with CH₂Cl₂/ acetone (20:1) to yield the following dihydropyrimidines.


2.6: General procedure for the synthesis of phenolic imines:

General Method A: According to a procedure described by *Overman et al.*⁶




Benzaldehyde (0.76 g, 7.1 mmol) was added dropwise to a stirred slurry of 2-aminophenol (0.78 g, 7.1 mmol), anhydrous MgSO₄ (2.5 g), and THF (5 mL) at 0 °C, and the reaction was allowed to warm to rt. After 8 h, the reaction mixture was filtered and the filtrate was concentrated to give 1.43 g (100 %) of the crude imine, which was further purified by recrystallized with Toluene.

General Method B: According to a procedure described by *Cheon et al.*⁷



To a 150 mL round bottom flask was added o-Aminophenol (10 mmol; 1.0 equiv) and aldehyde (10 mmol; 1.0 equiv) were dissolved in absolute EtOH (80 mL). Then, the reaction mixture was stirred at 80 °C for 3-5 h under argon atmosphere. When the starting materials were consumed completely (monitored by TLC), the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was recrystallized with EtOH. The solid was collected by filtration and washed with cooled EtOH to give the corresponding imine.


3. General procedure for Photoredox Synthesis of 2-Substituted Pyrimidines.



Under air atmosphere, a 15 mL reaction tube equipped with a magnetic stir bar, dihydropyrimidines **1** (0.10 mmol), TBA-eosinY (0.1 mmol%) and K₂CO₃ (0.20 mmol) was added, then MeOH (5.0 mL) and H₂O (0.5 mL) were added. The solution mixture was stirred in open air with a


3 W 450 nm blue LEDs irradiated and monitored by TLC. On the completion of the reaction, the reaction mixture was concentrated *in vacuo*. The residue was dissolved with bits of methylene chloride, The crude residue was purified by flash chromatography to yield the corresponding 2-substituted pyrimidines **2**.

4. General procedure for Photoredox Synthesis of 2-Substituted Benzoxazoles.




In a dried 10 mL reaction tube equipped with a magnetic stir bar, imine **3** (0.10 mmol) and TBA-eosinY (0.001 mmol) dissolved in dry PhCF₃ (3.0 mL) were added, then DBU (0.20 mmol) was added to the reaction system. Then the solution mixture was stirred at room temperature in an open flask with a 3 W 450 nm blue LEDs irradiated and monitored by TLC. On the completion of the reaction, the reaction mixture was quenched with H₂O, and extracted with Et₂O. The organic layer was collected, dried over Na₂SO₄, and the solvent removed *in vacuo*. The crude residue was purified by flash chromatography to yield the corresponding 2-substituted benzoxazole as white solid.

5. Gram scale dehydrogenative oxidation reaction under ambient sunlight



Under air atmosphere, a 250 mL round flask equipped with a magnetic stir bar, dihydropyrimidines **1a** (3.0 mmol), TBA-eosinY (0.1 mmol%) and K₂CO₃ (6.0 mmol) was added, then MeOH (150 mL) and H₂O (15 mL) were added. The solution mixture was stirred in open air with sunshine irradiated and monitored by TLC. On the completion of the reaction, the reaction mixture was quenched with H₂O, and extracted with Et₂O. The organic layer was collected, dried over Na₂SO₄, and the solvent removed *in vacuo*. The crude residue was purified by flash chromatography to afford the desired product **2a**.


6 The electrochemistry of DHPMs 1a.



Cyclic voltammogram of **1a** (1.0 mmol.L^{-1}) with 0.1 mol.L^{-1} $n\text{-Et}_4\text{NBF}_4$ in a mixture of methanol and water (10:1 v/v) in the absence (A) and presence (B) of K_2CO_3 (2.0 mmol.L^{-1}).

7 Optimization of photocatalytic aerobic preparation of 2-phenylbenzoxazole.

Variations to standard aromatization Reaction conditions for synthesis of 2-Arylbenzoxazole.^a



Entry	Solvent	Base	H ₂ O ^b	t (h) ^c	Yield (%) ^d
1	MeOH	K ₂ CO ₃	+	2	55
2	MeOH	K ₂ CO ₃	-	3	62
3	MeOH	DBU	-	3	80
4	CH ₃ CN	K ₂ CO ₃	-	3	71
5	CH ₃ CN	2,6-Lutidine	-	3	75
6	CH ₃ CN	DBU	-	3	79
7	CH ₂ Cl ₂	DBU	-	3	81
8	PhCH ₃	DBU	-	3	83
9	PhCF ₃	K ₂ CO ₃	-	3	66
10^e	PhCF₃	DBU	-	3	90
11 ^f	PhCF ₃	DBU	-	3	77

^a Reaction conditions: **3a** (0.1 mmol), TBA-eosinY (1 mol %). Base (0.2 mmol), Solvent 3 mL, Air, 3 W 450 nm LED visible-light irradiation.

^b "+" implies 0.5 mL of water was added to the system.


^c The time when **1a** was no longer consumed (monitored by TLC).

^d Isolated yield (average of two parallel experiments).

^e DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene.

^f An Eosin Y Disodium Salt was used instead of TBA-eosinY.

8. Study The Role of DBU by Transient Absorption Difference Spectra.




Transient absorption difference spectra of TBA-eosin Y ($1.0 \times 10^{-5} \text{ mol.L}^{-1}$) with 532 nm light in anaerobic methanol. Figure A: In the absence of additives. Figure B: In presence of DBU ($2.0 \times 10^{-3} \text{ mol.L}^{-1}$). Figure C: In presence of **3a** ($1.0 \times 10^{-3} \text{ mol.L}^{-1}$). Figure D: In presence of **3a** ($1.0 \times 10^{-3} \text{ mol.L}^{-1}$) and DBU ($2.0 \times 10^{-3} \text{ mol.L}^{-1}$).

The mechanism studies of the dehydrogenation of phenolic imines **3a** was also studied by transient absorption difference spectra. When an anaerobic methanol solution containing TBA-eosin Y ($1.0 \times 10^{-5} \text{ mol.L}^{-1}$) and DBU ($2.0 \times 10^{-3} \text{ mol.L}^{-1}$) was excited by a 532 nm laser pulse, the transient

absorption difference spectra between 390 nm and 450 nm is transparent (Figure B). On the contrary, a typical absorption of TBA-eosin Y radical anion at 406 nm was clearly observed upon flash-photolysis of an anaerobic solution containing TBA-eosin Y ($1.0 \times 10^{-5} \text{ mol.L}^{-1}$) and DBU ($2.0 \times 10^{-3} \text{ mol.L}^{-1}$) and **3a** ($1.0 \times 10^{-3} \text{ mol.L}^{-1}$) (Figure D). Combining the spectra of TBA-eosin Y (Figure A) and the spectra of TBA-eosin Y with **3a** (Figure C), it is clear that the organic base DBU is only used to dissociate the phenol to its anion, just as the role of inorganic base K_2CO_3 for the dehydrogenation of DHPMs **1a**.


9. Characterization Data of the 2-Substituted dihydropyrimidines.

Ethyl 6-methyl-2-(methylthio)-4-phenyl-1,4-dihydropyrimidine-5-carboxylate (**1a**):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.35-7.22 (m, 5H), 6.35 (brs, 1H), 5.66 (brs, 1H), 4.14-4.08 (q, $J = 7.2$ Hz, 2H), 2.46 (s, 3H), 2.37 (s, 3H), 1.21 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.7, 144.6, 128.3, 127.3, 126.9, 59.8, 14.2, 13.5 ppm.

Methyl 6-methyl-2-(methylthio)-4-phenyl-1,4-dihydropyrimidine-5-carboxylate (**1b**):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.32-7.20 (m, 5H), 6.44 (s, 1H), 5.62 (s, 1H), 3.63 (s, 3H), 2.42 (s, 3H), 2.32 (s, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 167.3, 144.5, 128.4, 126.8, 51.0, 13.5 ppm.

Ethyl 4-(4-methoxyphenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (**1c**):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.26-7.18 (m, 2H), 6.85-6.80 (m, 2H), 6.39 (s, 1H), 5.62 (s, 1H), 4.13-4.06 (m, 2H), 3.77 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H), 1.20 (t, 3H, $J = 7.2$ Hz) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.8, 158.8, 137.3, 128.0, 114.1, 113.6, 60.4, 59.7, 55.2, 14.2, 13.5 ppm.

Ethyl 4-(4-ethoxyphenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1d):




Pale yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.26-7.07 (m, 2H), 6.80 (d, $J = 8.8$ Hz, 2H), 6.62 (s, 1H), 5.56 (s, 1H), 4.09 (q, $J = 7.2$ Hz, 2H), 3.99 (q, $J = 7.2$ Hz, 2H), 2.44 (s, 3H), 2.35 (s, 3H), 1.39 (t, $J = 7.2$ Hz, 3H), 1.20 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.7, 158.2, 136.8, 128.0, 114.2, 63.3, 59.8, 14.8, 14.2, 13.6 ppm.

Tert-butyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1e):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.91 (s, 1H), 6.81 (dd, $J = 2.0, 6.4$ Hz, 1H), 6.76 (d, $J = 8.4$ Hz, 1H), 6.57 (brs, 1H), 5.56 (brs, 1H), 3.82 (s, 6H), 2.43 (s, 3H), 2.30 (s, 3H), 1.37 (s, 9H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 165.9, 148.5, 148.0, 137.2, 118.6, 110.7, 110.3, 80.1, 55.7, 28.14, 28.09, 13.6 ppm.

Ethyl 4-(benzo[d][1,3]dioxol-5-yl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1f):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.82 (d, $J = 1.2$ Hz, 1H), 6.77 (dd, $J = 1.6, 6.4$ Hz, 1H), 6.70 (d, $J = 8.0$ Hz, 1H), 5.90 (s, 2H), 5.53 (s, 1H), 4.09 (q, $J = 7.2$ Hz, 2H), 2.42 (s, 3H), 2.32 (s, 3H), 1.20 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.7, 147.6, 146.7, 138.7, 120.1, 107.9, 107.5, 102.3, 100.9, 59.8, 57.6, 19.8, 14.2, 13.5 ppm.

Ethyl 4-(3-(benzyloxy)-4-methoxyphenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1g):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): 7.41 (d, $J = 7.2$ Hz, 2H), 7.33 (t, $J = 7.2$ Hz, 2H), 7.27 (d, $J = 14.4$ Hz, 1H), 6.90 (d, $J = 1.2$ Hz, 1H), 6.85 (d, $J = 8.4$ Hz, 1H), 6.78 (d, $J = 8.0$ Hz, 1H), 5.52 (s, 1H), 5.11 (s, 2H), 4.09-4.01 (m, 2H), 3.82 (s, 3H), 2.34 (s, 3H), 2.25 (s, 3H), 1.17 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.7, 148.6, 147.7, 137.4, 137.0, 128.3, 127.6, 127.2, 119.3, 112.9, 111.2, 59.6, 57.5, 55.8, 53.3, 14.1, 13.4 ppm.

Ethyl 4-(4-isopropylphenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1h):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.26-7.23 (m, 2H), 7.14 (d, $J = 8.0$ Hz, 2H), 6.26 (brs, 1H), 5.61 (brs, 1H), 4.10 (q, $J = 7.2$ Hz, 2H), 2.90-2.83 (m, 1H), 2.44 (s, 3H), 2.33 (s, 3H), 1.23-1.19 (m, 9H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.9, 142.1, 126.7, 126.4, 59.8, 33.7, 23.9, 14.2, 13.5 ppm.

Methyl 4-(4-chlorophenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1i):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.26 (s, 4H), 6.64 (brs, 1H), 5.61 (brs, 1H), 3.65 (s, 3H), 2.42 (s, 3H), 2.34 (s, 3H) ppm; $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 167.0, 142.9, 132.9, 128.5, 128.3, 51.2, 13.6 ppm.

Ethyl 6-methyl-2-(methylthio)-4-(4-(trifluoromethyl)phenyl)-1,4-dihydropyrimidine-5-carboxylate (1j):




Yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.55 (d, $J = 8.0$ Hz, 2H), 7.44 (d, $J = 8.0$ Hz, 2H), 6.36 (brs, 1H), 5.75 (brs, 1H), 4.12 (q, $J = 7.2$ Hz, 2H), 2.43 (s, 3H), 2.35 (s, 3H), 1.21 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.5, 127.2, 125.3, 60.0, 14.2, 13.5 ppm.

Methyl 4-(2,4-dichlorophenyl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1k):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.39 (s, 1H), 7.18 (d, $J = 1.2$ Hz, 2H), 6.12 (brs, 1H), 5.94 (brs, 1H), 3.59 (s, 3H), 2.44 (s, 3H), 2.38 (s, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.8, 129.9, 129.8, 129.5, 129.3, 127.4, 51.1, 14.0, 13.4 ppm.

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1l):




Yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.26 (t, $J = 6.0$ Hz, 2H), 6.96 (t, $J = 8.8$ Hz, 2H), 6.43 (brs, 1H), 5.58 (brs, 1H), 4.08 (q, $J = 7.2$ Hz, 3H), 2.44 (s, 3H), 1.20-1.12 (m, 9H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.4, 163.2, 160.8, 140.6, 128.4, 128.3, 115.2, 115.0, 59.8, 53.4, 19.9, 14.1, 13.5 ppm.

Ethyl 2-(methylthio)-4,6-diphenyl-1,4-dihydropyrimidine-5-carboxylate (1m):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.46-7.25 (m, 10H), 6.40 (brs, 1H), 5.73 (brs, 1H), 3.87 (q, $J = 7.2$ Hz, 2H), 2.47 (s, 3H), 0.86 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.3, 144.1, 129.1, 128.9, 128.5, 128.3, 128.0, 127.7, 127.6, 126.9, 59.9, 13.8, 13.6 ppm.

Ethyl 4-(4-chlorophenyl)-2-(methylthio)-6-phenyl-1,4-dihydropyrimidine-5-carboxylate (1n):




Pale yellow Solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.41-7.31 (m, 9H), 6.51 (brs, 1H), 5.76 (brs, 1H), 3.89 (q, $J = 7.2$ Hz, 2H), 2.50 (s, 3H), 0.87 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 165.9, 129.5, 129.3, 129.0, 128.7, 128.3, 128.2, 127.8, 60.1, 13.9, 13.6 ppm.

Ethyl 4-(4-methoxyphenyl)-2-(methylthio)-6-phenyl-1,4-dihydropyrimidine-5-carboxylate (1o):




Yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.39-7.37 (m, 7H), 6.89-6.87 (m, 2H), 5.67 (brs, 1H), 3.88 (q, $J = 7.2$ Hz, 2H), 3.81 (s, 3H), 2.49 (s, 3H), 0.88 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 171.1, 159.0, 157.4, 133.7, 131.2, 130.7, 130.1, 129.6, 128.7, 128.6, 124.5, 119.8, 116.9, 114.4, 113.2, 88.2, 55.2, 52.7, 51.6 ppm.

(E)-ethyl 6-methyl-2-(methylthio)-4-styryl-1,4-dihydropyrimidine-5-carboxylate (1p):




Pale yellow Solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.34 (d, $J = 7.2$ Hz, 2H), 7.29-7.25 (m, 2H), 7.19 (t, $J = 7.2$ Hz, 1H), 6.40 (d, $J = 15.6$ Hz, 1H), 6.17 (dd, $J = 6.4$ Hz, 9.2 Hz, 1H), 5.25 (s, 1H), 4.23-4.11 (m, 2H), 2.46 (s, 1H), 2.30 (s, 1H), 1.26 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.6, 136.9, 129.1, 128.9, 128.4, 127.3, 126.4, 59.8, 14.3, 13.6 ppm.

Ethyl 4-heptyl-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1q):




Pale yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.25 (brs, 1H), 4.50 (brs, 1H), 4.19-4.10 (m, 2H), 2.43 (s, 3H), 2.27 (s, 3H), 1.48-1.23 (m, 15H), 4.23-4.12 (m, 0.85 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 167.0, 59.6, 36.3, 31.8, 29.4, 29.2, 26.8, 24.5, 22.6, 14.3, 14.0, 13.6 ppm.

Ethyl 6-methyl-2-(methylthio)-4-propyl-1,4-dihydropyrimidine-5-carboxylate (1r):




Pale yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.44 (brs, 1H), 4.56 (brs, 1H), 4.21-4.13 (m, 2H), 2.48 (s, 3H), 2.30 (s, 3H), 1.54-1.26 (m, 7H), 0.91 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.9, 59.7, 53.6, 38.6, 20.1, 17.7, 14.3, 14.0, 13.7 ppm.

Ethyl 4-isopropyl-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1s):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.06 (brs, 1H), 4.41 (s, 1H), 4.21-4.10 (m, 2H), 2.48-2.46 (m, 3H), 2.30-2.28 (m, 3H), 1.80-1.76 (m, 1H), 1.29-1.25 (m, 3H), 0.90 (d, $J = 5.6$ Hz, 3H), 0.86-0.84 (m, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 167.5, 59.6, 34.9, 18.3, 16.9, 14.3, 13.64, 13.56 ppm.

Ethyl 4-cyclopropyl-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1t):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.72 (brs, 1H), 4.19-4.09 (m, 2H), 4.04 (d, $J = 7.6$ Hz, 1H), 2.44 (s, 3H), 2.29 (s, 3H), 1.25 (t, $J = 7.2$ Hz, 3H), 1.23-0.95 (m, 1H), 0.42-0.40 (m, 1H), 0.39-0.33 (m, 2H), 0.33-0.29 (m, 1H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 167.2, 102.6, 59.6, 56.3, 20.3, 17.0, 14.3, 13.6, 1.9, 1.7 ppm.

Ethyl 4-(furan-2-yl)-6-methyl-2-(methylthio)-1,4-dihydropyrimidine-5-carboxylate (1u):




Yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.31 (t, $J = 0.8$ Hz, 1H), 6.52 (brs, 1H), 6.26 (dd, $J = 2.0, 1.2$ Hz, 1H), 6.09 (d, $J = 2.8$ Hz, 1H), 5.77 (s, 1H), 4.14 (q, $J = 7.2$ Hz, 2H), 2.43 (s, 3H), 2.34 (s, 3H), 1.23 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.4, 141.7, 110.0, 105.5, 59.8, 14.2, 13.6 ppm.

Ethyl 2-methoxy-6-methyl-4-phenyl-1,4-dihydropyrimidine-5-carboxylate (1v):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.33-7.21 (m, 5H), 6.11 (brs, 1H), 5.53 (s, 1H), 4.05 (q, $J = 7.2$ Hz, 2H), 3.77 (s, 3H), 2.35 (s, 3H), 1.16 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.7, 128.4, 126.9, 59.6, 54.0, 14.1 ppm.

Ethyl 2-methoxy-4-(4-methoxyphenyl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate (1w):



Pale yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.24-7.21 (d, $J = 8.4$ Hz, 2H), 6.81 (d, $J = 8.4$ Hz, 2H), 5.46 (s, 1H), 4.05 (q, $J = 7.2$ Hz, 2H), 3.76-3.74 (m, 6H), 2.33 (s, 3H), 1.16 (t, $J = 7.2$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3): 166.8, 158.6, 137.9, 127.9, 113.5, 59.5, 55.1, 53.8, 53.4, 14.1.


Ethyl 4-(4-chlorophenyl)-2-methoxy-6-methyl-1,4-dihydropyrimidine-5-carboxylate (1x):



Yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.25 (s, 4H), 5.51 (brs, 1H), 4.06 (q, $J = 7.2$ Hz, 2H), 3.76 (s, 3H), 2.34 (s, 3H), 1.17 (t, $J = 7.2$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.5, 143.9, 132.9, 128.4, 128.3, 59.8, 54.1, 14.2 ppm.


10. Characterization Data of the 2-Substituted Pyrimidines.

Ethyl 4-methyl-2-(methylthio)-6-phenylpyrimidine-5-carboxylate (2a):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65-7.63 (m, 2H), 7.48-7.42 (m, 3H), 4.16 (q, $J = 7.2$ Hz, 2H), 2.62 (s, 3H), 2.57 (s, 3H), 1.04 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.4, 168.0, 165.4, 163.5, 137.7, 130.0, 128.4, 128.2, 120.9, 61.6, 22.5, 14.1, 13.5 ppm. **HRMS (ESI):** calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 289.1005; found 289.1007.

Methyl 4-methyl-2-(methylthio)-6-phenylpyrimidine-5-carboxylate (2b):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.66-7.64 (m, 2H), 7.46 (d, $J = 7.2$ Hz, 3H), 3.69 (s, 3H), 2.63 (s, 3H), 2.57 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.6, 168.7, 165.5, 163.4, 137.6, 130.2, 128.5, 128.2, 120.6, 52.4, 22.6, 14.1 ppm. **HRMS (ESI):** calcd for $\text{C}_{14}\text{H}_{15}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 275.0849; found 275.0857.

Ethyl 4-(4-methoxyphenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2c):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.66 (d, $J = 8.8$ Hz, 2H), 6.96 (d, $J = 8.8$ Hz, 2H), 4.22 (q, $J = 7.2$ Hz, 2H), 3.86 (s, 3H), 2.62 (s, 3H), 2.54 (s, 3H), 1.14 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.2, 168.5, 165.1, 162.7, 161.4, 130.04, 129.97, 120.4, 113.9, 61.7, 55.4, 22.5, 14.1, 13.8 ppm. **HRMS (ESI):** calcd for $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$ m/z 319.1111; found 319.1117.

Ethyl 4-(4-ethoxyphenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2d):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (d, $J = 8.8$ Hz, 2H), 6.95 (d, $J = 8.8$ Hz, 2H), 4.22 (q, $J = 7.2$ Hz, 2H), 4.09 (q, $J = 7.2$ Hz, 2H), 2.62 (s, 3H), 2.55 (s, 3H), 1.45 (t, $J = 7.2$ Hz, 3H), 1.14 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.0, 168.5, 165.0, 162.8, 160.9, 130.1, 129.6, 120.3, 114.4, 63.6, 61.8, 22.7, 22.4, 14.7, 14.2, 13.8 ppm. **HRMS (ESI):** calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$ m/z 333.1273; found 333.1271

Tert-butyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2e):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.31-7.26 (m, 2H), 6.91 (d, $J = 8.0$ Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 2.60 (s, 3H), 2.54 (s, 3H), 1.40 (s, 9H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 171.6, 167.5, 164.7, 162.4, 150.8, 148.9, 130.4, 122.2, 121.8, 111.7, 110.6, 82.8, 56.0, 27.8 ppm. **HRMS (ESI):** calcd for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ m/z 377.1530; found 377.1534.

Ethyl 4-(benzo[d][1,3]dioxol-5-yl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2f):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.22 (s, 1H), 7.16 (d, $J = 8.0$ Hz, 1H), 6.85 (d, $J = 8.0$ Hz, 1H), 6.02 (s, 2H), 4.23 (q, $J = 7.2$ Hz, 2H), 2.60 (s, 3H), 2.53 (s, 3H), 1.17 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.1, 168.3, 165.2, 162.4, 149.4, 147.9, 131.5, 123.0, 120.5, 108.8, 108.2, 101.5, 61.7, 22.5, 14.1, 13.8 ppm. **HRMS (ESI):** calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ m/z 333.0904; found 333.0908.

Ethyl 4-(3-(benzyloxy)-4-methoxyphenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2g):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.47 (d, $J = 7.2$ Hz, 2H), 7.40-7.24 (m, 5H), 6.93 (d, $J = 8.4$ Hz, 1H), 5.20 (s, 2H), 4.15 (q, $J = 7.2$ Hz, 2H), 3.94 (s, 3H), 2.53 (s, 6H), 1.12 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.0, 168.5, 165.0, 162.5, 151.5, 148.0, 136.7, 130.0, 128.6, 127.9, 127.2, 122.0, 120.4, 113.7, 111.0, 70.8, 61.7, 56.0, 22.4, 14.1, 13.8 ppm. **HRMS (ESI):** calcd for $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ m/z 425.1530; found 425.1525.

Ethyl 4-(4-isopropylphenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2h) :




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.59 (d, $J = 8.4$ Hz, 2H), 7.30 (d, $J = 8.4$ Hz, 2H), 4.18 (q, $J = 7.2$ Hz, 2H), 3.01-2.90 (m, 1H), 2.61 (s, 3H), 2.56 (s, 3H), 1.28 (s, 3H), 1.26 (s, 3H), 1.04 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.3, 168.2, 165.2, 163.5, 151.3, 135.1, 128.3, 126.5, 120.7, 61.6, 34.0, 26.8, 23.8, 22.5, 14.1, 13.5 ppm. **HRMS (ESI):** calcd for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 331.1475; found 331.1475.

Methyl 4-(4-chlorophenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2i) :




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.60 (d, $J = 8.4$ Hz, 2H), 7.43 (d, $J = 8.4$, 2H), 3.72 (s, 3H), 2.62 (s, 3H), 2.56 (s, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.8, 168.5, 165.7, 162.2, 136.6, 136.0, 129.6, 128.8, 120.4, 52.6, 22.7, 14.18, 14.16 ppm. **HRMS (ESI):** calcd for $\text{C}_{14}\text{H}_{14}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 309.0459; found 309.0461.

Ethyl 4-methyl-2-(methylthio)-6-(4-(trifluoromethyl)phenyl)pyrimidine-5-carboxylate (2j):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.76-7.70 (m, 4H), 4.17 (q, $J = 7.2$ Hz, 2H), 2.61 (s, 3H), 2.59 (s, 3H), 1.05 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.9, 167.6, 166.0, 162.3, 141.2, 132.0, 131.7, 128.7, 128.6, 125.4, 125.3, 122.4, 120.9, 61.9, 22.7, 14.2, 13.5 ppm. **HRMS (ESI):** calcd for $\text{C}_{16}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 357.0879; found 357.0881.

Methyl 4-(2,4-dichlorophenyl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2k):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.46 (d, $J = 1.6$ Hz, 1H), 7.36-7.27 (m, 2H), 3.65 (s, 3H), 2.67 (s, 3H), 2.59 (s, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 173.4, 166.9, 166.7, 162.8, 136.0, 135.6, 132.9, 130.9, 129.4, 127.1, 121.0, 52.3, 23.7, 14.2 ppm. **HRMS (ESI):** calcd for $\text{C}_{14}\text{H}_{13}\text{Cl}_2\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 343.0069; found 343.0071.

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylthio)pyrimidine-5-carboxylate (2l):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.67-7.64 (m, 2H), 7.15-7.11 (m, 2H), 4.18 (q, $J = 7.2$ Hz, 2H), 3.21-3.15 (m, 1H), 2.62 (s, 3H), 1.32 (d, $J = 6.4$ Hz, 6H), 1.10 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 173.1, 172.6, 168.2, 165.1, 162.5 (d, $J = 300.0$ Hz), 133.9 (d, $J = 3.0$ Hz), 130.4 (d, $J = 8.0$ Hz), 120.2, 115.5 (d, $J = 21.0$ Hz), 61.8, 33.2, 21.6, 14.2, 13.7 ppm. **HRMS (ESI):** calcd for $\text{C}_{17}\text{H}_{20}\text{FN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 335.1224; found 335.1230.

Ethyl 2-(methylthio)-4,6-diphenylpyrimidine-5-carboxylate (2m):




White solid. $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.72-7.69 (m, 4H), 7.50-7.44 (m, 6H), 4.05 (q, $J = 7.2$ Hz, 2H), 2.67 (s, 3H), 0.95 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (CDCl_3 , 100 MHz): δ 172.7, 168.1, 164.3, 137.4, 130.1, 128.43, 128.37, 120.8, 61.8, 14.3, 13.4 ppm. **HRMS (ESI):** calcd for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 351.1162; found 351.1166.

Ethyl 4-(4-chlorophenyl)-2-(methylthio)-6-phenylpyrimidine-5-carboxylate (2n):




White solid. $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.70-7.64 (m, 4H), 7.50-7.44 (m, 5H), 4.06 (q, $J = 7.2$ Hz, 2H), 2.66 (s, 3H), 0.97 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (CDCl_3 , 100 MHz): δ 172.9, 167.9, 164.5, 163.0, 137.3, 136.4, 135.8, 130.2, 129.8, 128.7, 128.5, 128.3, 120.6, 61.9, 14.3, 13.4 ppm. **HRMS (ESI):** calcd for $\text{C}_{20}\text{H}_{18}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 385.0772; found 385.0770.

Ethyl 4-(4-methoxyphenyl)-2-(methylthio)-6-phenylpyrimidine-5-carboxylate (2o):




White solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.71-7.66 (m, 4H), 7.48-7.46 (m, 3H), 6.98 (dd, $J = 2.0, 6.8$ Hz, 2H), 4.07 (q, $J = 7.2$ Hz, 2H), 3.87 (s, 3H), 2.66 (s, 3H), 0.98 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.4, 168.5, 164.3, 163.5, 161.3, 137.5, 130.1, 129.9, 129.6, 128.4, 128.3, 120.3, 113.9, 61.8, 55.4, 14.3, 13.5 ppm. **HRMS (ESI):** calcd for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$ m/z 381.1267; found 381.1271.

(E)-ethyl 4-methyl-2-(methylthio)-6-styrylpyrimidine-5-carboxylate (2p):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.10 (d, $J = 15.6$ Hz, 1H), 7.58 (d, $J = 6.8$ Hz, 2H), 7.42-7.36 (m, 3H), 7.20 (d, $J = 15.2$ Hz, 1H), 4.48 (q, $J = 7.2$ Hz, 2H), 2.65 (s, 3H), 2.53 (s, 3H), 1.45 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.0, 167.4, 165.7, 159.0, 139.2, 135.7, 129.5, 128.8, 127.9, 122.3, 119.9, 61.8, 23.2, 14.3, 14.1 ppm. **HRMS (ESI):** calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 315.1162; found 315.1160.

Ethyl 4-heptyl-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2q):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 4.38 (q, $J = 7.2$ Hz, 2H), 2.70 (t, $J = 8.0$ Hz, 2H), 2.55 (s, 3H), 2.46 (s, 3H), 1.72-1.64 (m, 2H), 1.38 (t, $J = 7.2$ Hz, 3H), 1.31-1.25 (m, 8H), 0.86 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.0, 168.1, 167.6, 164.5, 121.5, 61.6, 35.8, 31.6, 29.4, 29.0, 28.7, 22.8, 22.6, 14.1, 14.01, 13.99 ppm. **HRMS (ESI):** calcd for $\text{C}_{16}\text{H}_{27}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 311.1787; found 311.1786.

Ethyl 4-methyl-2-(methylthio)-6-propylpyrimidine-5-carboxylate (2r):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 4.39 (q, $J = 7.2$ Hz, 2H), 2.70 (t, $J = 7.6$ Hz, 2H), 2.56 (s, 3H), 2.47 (s, 3H), 1.79-1.69 (m, 2H), 1.39 (t, $J = 7.2$ Hz, 3H), 0.96 (t, $J = 7.6$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.1, 167.9, 167.7, 164.6, 121.7, 61.6, 37.7, 22.9, 22.0, 14.1, 14.03, 13.95 ppm. **HRMS (ESI):** calcd for $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 255.1162; found 255.1165.

Ethyl 4-isopropyl-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2s):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 4.40 (q, $J = 7.2$ Hz, 2H), 3.11-3.01 (m, 1H), 2.57 (s, 3H), 2.45 (s, 3H), 1.39 (t, $J = 7.2$ Hz, 3H), 1.25 (s, 3H), 1.25 (s, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.1, 172.0, 167.9, 164.2, 121.1, 61.7, 33.4, 22.6, 21.6, 14.1, 14.0 ppm. **HRMS (ESI):** calcd for $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 255.1162; found 255.1169.

Ethyl 4-cyclopropyl-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2t):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 4.42 (q, $J = 7.2$ Hz, 2H), 2.49 (s, 3H), 2.46 (s, 3H), 2.13-2.08 (m, 1H), 1.40 (t, $J = 7.6$ Hz, 3H), 1.28-1.24 (m, 2H), 1.06-1.04 (m, 2H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 172.0, 169.0, 167.9, 163.7, 121.2, 61.7, 22.8, 14.5, 14.2, 13.9, 11.8 ppm. **HRMS (ESI):** calcd for $\text{C}_{12}\text{H}_{17}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ m/z 253.1005; found 253.1004.

Ethyl 4-(furan-2-yl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (2u):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.55 (s, 1H), 7.33 (d, $J = 3.2$ Hz, 1H), 6.57 (q, $J = 1.6$ Hz, 2H), 4.44 (q, $J = 7.2$ Hz, 2H), 2.61 (s, 3H), 2.49 (s, 3H), 1.37 (t, $J = 7.6$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 171.9, 167.8, 164.9, 150.94, 150.85, 145.4, 117.5, 114.6, 112.4, 61.9, 29.7, 22.7, 22.2, 14.1 ppm. **HRMS (ESI):** calcd for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$ m/z 279.0798; found 279.0796.

Ethyl 2-methoxy-4-methyl-6-phenylpyrimidine-5-carboxylate (2v):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (dd, $J = 1.6, 6.0$ Hz, 2H), 7.47-7.42 (m, 3H), 4.15 (q, $J = 7.2$ Hz, 2H), 4.08 (s, 3H), 2.58 (s, 3H), 1.40 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 168.7, 168.3, 166.4, 164.5, 137.8, 130.1, 128.4, 128.2, 119.8, 61.6, 55.0, 22.8, 13.6 ppm. **HRMS (ESI):** calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ m/z 273.1234; found 273.1238.

Ethyl 2-methoxy-4-(4-methoxyphenyl)-6-methylpyrimidine-5-carboxylate (2w):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.66-7.62 (m, 2H), 6.95-6.91 (m, 2H), 4.19 (q, $J = 7.2$ Hz, 2H), 4.04 (s, 3H), 3.83 (s, 3H), 2.53 (s, 3H), 1.11 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): 168.6, 168.2, 165.4, 164.3, 161.2, 129.9, 119.2, 113.7, 61.5, 55.2, 54.8, 22.6, 13.7 ppm. **HRMS (ESI):** calcd for $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$ m/z 303.1339; found 303.1340.

Ethyl 4-(4-chlorophenyl)-2-methoxy-6-methylpyrimidine-5-carboxylate (**2x**):




White oil. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (dd, $J = 2.0, 4.8$ Hz, 2H), 7.42 (dd, $J = 1.6, 5.2$ Hz, 2H), 4.19 (q, $J = 7.2$ Hz, 2H), 4.08 (s, 3H), 2.58 (s, 3H), 1.11 (t, $J = 7.2$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 168.9, 168.1, 165.2, 164.4, 136.4, 136.1, 129.7, 128.7, 119.7, 61.8, 55.1, 22.8, 13.7 ppm. **HRMS (ESI)**: calcd for $\text{C}_{15}\text{H}_{16}\text{ClN}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ m/z 307.0844; found 307.0851.


11. Characterization Data of the 2-Substituted Benzoxazoles.



2-phenylbenzo[d]oxazole (4a): The general procedure was followed using (E)-2-(benzylideneamino)phenol (19.7 mg, 0.10 mmol). Purification by column chromatography (PE \rightarrow PE/EtOAc = 40:1) yielded **4a** (17.6 mg, 90%) as a white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.29-8.27 (m, 2H), 7.82-7.78 (m, 1H), 7.62-7.58 (m, 1H), 7.56-7.53 (m, 3H), 7.39-7.35 (m, 2H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 163.0, 150.7, 142.0, 131.5, 128.9, 127.6, 127.1, 125.1, 124.6, 120.0, 110.6 ppm. **MS (ESI)**: calculated for $[\text{C}_{13}\text{H}_{10}\text{NO}]^+$: 196.08, found 196.03.




2-(p-tolyl)benzo[d]oxazole(4b): The general procedure was followed using (E)-2-((4-methylbenzylidene)amino)phenol (21.1 mg, 0.10 mmol). Purification by column chromatography (PE \rightarrow PE/EtOAc = 40:1) yielded **4b** (14.8 mg, 71%) as a white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.16 (d, $J = 8.4$ Hz, 2H), 7.78-7.76 (m, 1H), 7.59-7.57 (m, 1H), 7.36-7.33 (m, 4H), 2.45 (s, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 163.3, 150.7, 142.1, 129.6, 127.6, 124.9, 124.5, 124.3, 119.8, 110.5, 21.7 ppm. **MS (EI)**: calculated for $[\text{M}^+] = [\text{C}_{14}\text{H}_{11}\text{NO}]^+$: 209.08, found m/z (%) m/z (%) 209.9 (14.6), 208.9 (M^+ , 100.0), 207.9 (26.3), 206.8 (3.3), 180.9 (3.5), 179.9 (6.2), 148.8 (32.3), 104.0 (3.1), 90.9 (8.4), 89.9 (3.9), 62.9 (5.1).




2-(m-tolyl)benzo[d]oxazole (4c): The general procedure was followed using (E)-2-((3-methylbenzylidene)amino)phenol (21.5 mg, 0.10 mmol). Purification by column chromatography (PE \rightarrow PE/EtOAc


= 40:1) yielded **4c** (16.8 mg, 80%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.11 (s, 1H), 8.06 (d, *J* = 7.6 Hz, 1H), 7.81-7.78 (m, 1H), 7.60-7.56 (m, 1H), 7.44-7.40 (m, 1H), 7.38-7.35 (m, 3H), 2.46 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 163.2, 150.7, 142.0, 138.7, 132.3, 128.8, 128.1, 126.9, 125.0, 124.7, 124.5, 119.9, 110.5, 21.3 ppm. **MS (EI):** calculated for [M⁺] = [C₁₄H₁₁NO]⁺: 209.08, found *m/z* (%) 208.9 (M⁺, 100.0), 179.8 (9.3), 104.4 (4.0), 90.9 (8.5), 62.9 (6.3).




2-(o-tolyl)benzo[d]oxazole (4d): The general procedure was followed using (E)-2-((2-methylbenzylidene)amino)phenol (21.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4d** (16.1 mg, 80%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.20 (d, *J* = 2.0 Hz, 1H), 8.18-7.80 (m, 1H), 7.63-7.59 (m, 1H), 7.45-7.41 (m, 1H), 7.40-7.35 (m, 4H), 2.83 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 163.4, 150.3, 142.1, 138.8, 131.8, 130.9, 129.9, 126.2, 126.1, 125.0, 124.3, 120.1, 110.5, 22.2 ppm. **MS (ESI):** calculated for [C₁₄H₁₂NO]⁺: 210.09, found 210.15.



2-(4-methoxyphenyl)benzo[d]oxazole (4e): The general procedure was followed using (E)-2-((4-methoxybenzylidene)amino)phenol (22.7 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 20:1) yielded **4e** (21.6 mg, 96%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.21 (d, *J* = 8.8 Hz, 2H), 7.76-7.73 (m, 1H), 7.57-7.55 (m, 1H), 7.36-7.30 (m, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 3.90 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 163.1, 162.3, 150.6, 142.2, 129.3, 124.6, 124.4, 119.7, 119.6, 114.3, 110.3, 55.4 ppm. **MS (ESI):** calculated for [C₁₄H₁₂NO₂]⁺: 226.09, found 226.14.




2-(3-methoxyphenyl)benzo[d]oxazole (4f): The general procedure was followed using (E)-2-((3-methoxybenzylidene)amino)phenol (23.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 20:1) yielded **4f** (19.7 mg, 87%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 7.87 (d, *J* = 8.0 Hz, 1H), 7.81-7.79 (m, 2H), 7.62-7.59 (m, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.40-7.35 (m, 2H), 7.12-7.09 (m, 2H), 3.94 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 162.9, 159.9, 150.7, 142.0, 130.0, 128.3, 125.2, 124.6, 120.1, 120.0, 118.4, 111.8, 110.6, 55.5 ppm. **MS (EI):** calculated for [M⁺] = [C₁₄H₁₁NO₂]⁺: 225.08, found *m/z* (%) 225.9 (13.9), 224.9 (M⁺, 100.0), 223.9 (48.8), 195.9 (10.9), 194.9 (20.3), 193.8 (4.4), 181.8 (5.5), 166.8 (5.7), 126.9 (3.1), 112.4 (4.9), 91.9 (3.0), 76.9 (2.8), 63.9 (4.6), 62.8 (5.3), 43.8 (3.0).




2-(2-methoxyphenyl)benzo[d]oxazole (4g): The general procedure was followed using (E)-2-((2-methoxybenzylidene)amino)phenol (22.6 mg, 0.10 mmol). Purification by column chromatography


(PE→PE/EtOAc = 20:1) yielded **4g** (18.5 mg, 83%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.15 (dd, *J* = 1.6, 6.0 Hz, 1H), 7.84-7.81 (m, 1H), 7.60-7.58 (m, 1H), 7.52-7.48 (m, 2H), 7.35-7.07 (m, 2H), 4.02 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 161.5, 158.4, 150.3, 142.1, 132.7, 131.2, 124.9, 124.2, 120.7, 120.2, 116.1, 112.0, 110.4, 56.2 ppm. **MS (ESI):** calculated for [C₁₄H₁₂NO₂]⁺: 226.09, found 226.03.




2-(4-chlorophenyl)benzo[d]oxazole (4h): The general procedure was followed using (E)-2-((4-chlorobenzylidene)amino)phenol (23.2 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4h** (21.6 mg, 94%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.20 (d, *J* = 8.4 Hz, 2H), 7.79-7.76 (m, 1H), 7.60-7.58 (m, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.40-7.36 (m, 2H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 162.1, 150.8, 142.1, 137.8, 129.3, 128.9, 125.7, 125.4, 124.8, 120.2, 110 ppm. **MS (ED):** calculated for [M⁺] = [C₁₃H₈ClNO]⁺ : 229.03, found *m/z* (%) 230.9 (31.9), 229.9 (14.6), 228.8 (M⁺, 100.0), 202.9 (3.4), 200.8 (10.1), 165.9 (6.0), 138.9 (2.1), 100.3 (3.6), 91.9 (3.7), 63.9 (5.5), 62.9 (6.5).



2-(3-chlorophenyl)benzo[d]oxazole (4i): The general procedure was followed using (E)-2-((3-chlorobenzylidene)amino)phenol (23.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4i** (21.3 mg, 93%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.26 (d, *J* = 2.0 Hz, 1H), 8.16-8.13 (m, 1H), 7.81-7.77 (m, 1H), 7.62-7.57 (m, 1H), 7.52-7.50 (d, *J* = 8.4 Hz, 2H), 7.40-7.36 (m, 2H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 161.6, 150.7, 141.9, 135.0, 131.5, 130.2, 128.8, 127.6, 125.6, 125.5, 124.8, 120.2, 110.7 ppm. **MS (ESI):** calculated for [C₁₃H₉ClNO]⁺: 230.04, found 229.99.




2-(2-chlorophenyl)benzo[d]oxazole (4j): The general procedure was followed using (E)-2-((2-chlorobenzylidene)amino)phenol (23.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4j** (20.4 mg, 89%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.11-8.09 (dd, *J* = 8.0 Hz, 1H), 7.86-7.81 (m, 1H), 7.57-7.54 (m, 1H), 7.51-7.48 (m, 1H), 7.37-7.31 (m, 4H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 160.6, 150.3, 141.5, 133.2, 131.6, 131.5, 131.1, 126.6, 125.9, 125.3, 124.4, 120.2, 110.5 ppm. **MS (ED):** calculated for [M⁺] = [C₁₃H₈ClNO]⁺ : 229.03, found *m/z* (%) 230.8 (33.0), 229.9 (16.6), 228.7 (M⁺, 100.0), 202.8 (5.8), 200.7 (19.2), 193.9 (2.0), 165.9 (8.4), 138.9 (2.6), 114.3 (2.2), 101.8 (2.5), 100.3 (6.5), 91.8 (6.9), 82.4 (3.9), 63.9 (8.5), 62.9 (10.5).




2-(4-fluorophenyl)benzo[d]oxazole (4k) : The general procedure was followed using (E)-2-((4-


fluorobenzylidene)amino)phenol (21.5 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4k** (16.0 mg, 75%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.30-8.25 (m, 2H), 7.80-7.76 (m, 1H), 7.60-7.57 (m, 1H), 7.39-7.35 (m, 2H), 7.25-7.20 (m, 2H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 166.1, 163.5, 162.1, 150.7, 142.0, 129.9 (d, *J* = 9.0 Hz), 125.1, 124.7, 123.5 (d, *J* = 3.0 Hz), 120.0, 116.2 (d, *J* = 22.0 Hz), 110.6 ppm. **MS (ESI):** calcd for [C₁₃H₉FNO]⁺: 214.07; found 214.10.




2-(4-bromophenyl)benzo[d]oxazole (4l): The general procedure was followed using (E)-2-((4-bromobenzylidene)amino)phenol (27.5 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4l** (23.0 mg, 84%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.12 (d, *J* = 7.2 Hz, 2H), 7.80-7.75 (m, 1H), 7.66 (d, *J* = 8.8 Hz, 2H), 7.60-7.56 (m, 1H), 7.39-7.35 (m, 2H). ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 162.1, 150.7, 142.0, 132.2, 129.0, 128.9, 126.2, 126.1, 125.4, 125.1, 124.7, 120.1, 120.0, 110.6 ppm. **MS (ESI):** calculated for [C₁₃H₉BrNO]⁺: 273.99, found 274.07.



2-(4-(trifluoromethyl)phenyl)benzo[d]oxazole (4m): The general procedure was followed using (E)-2-((4-(trifluoromethyl)benzylidene)amino)phenol (26.5 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 20:1) yielded **4m** (21.6 mg, 82%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.39 (d, *J* = 8.0 Hz, 2H), 7.84-7.79 (m, 3H), 7.64-7.60 (m, 1H), 7.44-7.38 (m, 2H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 161.5, 150.8, 141.9, 133.1, 132.8, 130.4, 127.8, 126.0, 125.9, 125.9, 125.8, 125.1, 124.9, 122.4, 120.4, 110.8 ppm. **MS (EI):** calculated for [M⁺] = [C₁₃H₈BrNO]⁺: 263.06, found m/z (%) 263.9 (14.4), 262.8 (M⁺, 100.0), 243.9 (6.3), 234.7 (19.2), 144.8 (3.4), 131.4 (3.8), 117.4 (3.1), 92.1 (7.1), 63.9 (7.7), 62.9 (7.6).




4-(benzo[d]oxazol-2-yl)benzotrile (4n): The general procedure was followed using (E)-4-(((2-hydroxyphenyl)imino)methyl)benzotrile (22.2 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **4n** (17.4 mg, 79%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.38 (d, *J* = 8.8 Hz, 2H), 7.85-7.82 (m, 3H), 7.65-7.62 (m, 1H), 7.46-7.40 (m, 2H). ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 160.9, 150.9, 141.8, 132.7, 131.1, 127.9, 126.2, 125.1, 120.6, 118.2, 114.7, 110.9 ppm. **MS (EI):** calculated for [M⁺] = [C₁₄H₈N₂O]⁺: 220.06, found m/z (%) 220.9 (14.9), 219.8 (M⁺, 100.0), 209.9 (4.2), 191.9 (10.2), 146.9 (2.4), 96.0 (3.2), 91.8 (2.6), 63.9 (5.6), 62.9 (6.2), 43.8 (6.9).




2-(4-(tert-butyl)phenyl)benzo[d]oxazole (4o): The general procedure was followed using (E)-2-


-((4-(tert-butyl)benzylidene)amino)phenol (25.3 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4o** (23.6 mg, 94%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 8.20 (d, *J* = 8.8 Hz, 2H), 7.80-7.77 (m, 1H), 7.60-7.55 (m, 3H), 7.37-7.34 (m, 2H), 1.39 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 163.2, 155.1, 150.7, 142.2, 127.4, 125.9, 124.8, 124.4, 124.3, 119.8, 110.5, 35.0, 31.1 ppm. MS (EI): calculated for [M⁺] = [C₁₇H₁₇NO]⁺ : 251.13, found *m/z* (%) 252.0 (6.9), 250.8 (M⁺, 44.0), 237.0 (16.8), 235.9 (100.0), 233.9 (2.9), 219.9 (3.6), 207.9 (14.3), 206.9 (2.6), 195.9 (3.1), 104.2 (6.3), 103.5 (6.8).




2-(4-(chloromethyl)phenyl)benzo[d]oxazole (4p): The general procedure was followed using (E)-2-((4-(chloromethyl)benzylidene)amino)phenol (24.6 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4p** (22.6 mg, 93%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 8.27 (d, *J* = 8.4 Hz, 2H), 7.81-7.78 (m, 1H), 7.62-7.56 (m, 3H), 7.39-7.37 (m, 2H), 4.66 (s, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 162.4, 150.8, 142.0, 140.8, 129.1, 128.0, 127.1, 125.3, 124.7, 110.6, 45.5 ppm. MS (ESI): calculated for [C₁₄H₁₁ClNO]⁺: 244.05, found 244.00.




2-([1,1'-biphenyl]-4-yl)benzo[d]oxazole (4q): The general procedure was followed using (E)-2-((([1,1'-biphenyl]-4-ylmethylene)amino)phenol (27.3 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4q** (23.6 mg, 87%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 8.35 (d, *J* = 8.4 Hz, 2H), 7.82-7.77 (m, 3H), 7.70-7.68 (m, 2H), 7.63-7.61 (m, 1H), 7.52-7.50 (m, 2H), 7.48-7.37 (m, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 162.9, 150.8, 144.2, 142.2, 140.0, 128.9, 128.1, 127.6, 127.2, 125.9, 125.1, 124.6, 120.0, 110.6 ppm. MS (EI): calculated for [M⁺] = [C₁₉H₁₃NO]⁺ : 271.10, found *m/z* (%) 271.9 (18.5), 270.9 (M⁺, 100.0), 269.6 (6.8), 242.9 (4.7), 240.9 (3.4), 178.9 (1.8), 177.9 (1.6), 152.9 (2.5), 151.9 (9.0), 150.9 (3.8), 135.7 (6.0), 135.1 (5.2), 63.9 (2.6), 62.9 (2.9).




2-(naphthalen-1-yl)benzo[d]oxazole (4r): The general procedure was followed using (E)-2-((naphthalen-1-ylmethylene)amino)phenol (24.7 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4r** (21.3 mg, 87%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 9.51 (d, *J* = 8.4 Hz, 1H), 8.47-8.44 (m, 1H), 8.05 (d, *J* = 8.0 Hz, 1H), 7.97-7.91 (m, 2H), 7.76-7.72 (m, 1H), 7.68-7.60 (m, 3H), 7.45-7.41 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 162.7, 150.1, 142.2, 133.9, 132.3, 130.6, 129.3, 128.6, 127.9, 126.4, 126.2, 125.2, 124.9, 124.4, 123.5, 120.2, 110.5 ppm. MS (EI): calculated for [M⁺] = [C₁₇H₁₁NO]⁺ : 245.08, found *m/z* (%) 245.9 (13.0), 244.9 (M⁺, 79.0), 243.8 (100.0), 216.9 (2.1), 215.9 (9.7), 214.9 (3.3), 213.9 (2.3), 188.9 (2.7), 152.9 (4.7), 126.9 (6.0), 125.9 (3.6), 108.4 (2.9), 63.9 (2.3), 62.9 (3.3).




2-(2-chloro-4-fluorophenyl)benzo[d]oxazole (4s): The general procedure was followed using (E)-2-((2-chloro-4-fluorobenzylidene)amino)phenol (25.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **4s** (19.5 mg, 79%) as a white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.18 (dd, $J = 2.8, 6.0$ Hz, 1H), 7.86-7.84 (m, 1H), 7.63-7.61 (m, 1H), 7.43-7.33 (s, 2H), 7.32-7.17 (m, 1H), 7.16-7.13 (m, 1H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 164.9, 162.4, 160.1, 150.5, 141.6, 134.9, 134.9, 133.4, 133.3, 125.6, 124.7, 122.7, 122.7, 120.4, 118.9, 118.7, 114.7, 114.5, 110.7 ppm. **MS (ESI):** calculated for $[\text{C}_{13}\text{H}_8\text{ClFNO}]^+$: 248.03, found 247.98.



2-(2,4-dichlorophenyl)benzo[d]oxazole (4t): The general procedure was followed using (E)-2-((2,4-dichlorobenzylidene)amino)phenol (26.6 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4t** (18.9 mg, 71%) as a white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.14 (d, $J = 8.4$ Hz, 1H), 7.87-7.85 (m, 1H), 7.64-7.61 (m, 2H), 7.44-7.40 (m, 3H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 160.1, 150.5, 141.6, 137.6, 134.3, 132.5, 131.3, 127.5, 125.8, 124.8, 124.8, 120.6, 110.8 ppm. **MS (ESI):** calculated for $[\text{C}_{13}\text{H}_8\text{Cl}_2\text{NO}]^+$: 264.00, found 263.98.




2-(3,4-dichlorophenyl)benzo[d]oxazole (4u): The general procedure was followed using (E)-2-((3,4-dichlorobenzylidene)amino)phenol (27.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4u** (24.5 mg, 92%) as a white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.33 (d, $J = 2.0$ Hz, 1H), 8.07-8.04 (m, 1H), 7.78-7.76 (m, 1H), 7.59-7.57 (m, 2H), 7.39-7.37 (m, 2H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 160.8, 150.7, 141.8, 135.8, 133.4, 131.0, 129.2, 126.9, 126.4, 125.7, 124.9, 120.2, 110.7 ppm. **MS (EI):** calculated for $[\text{M}^+] = [\text{C}_{13}\text{H}_7\text{Cl}_2\text{NO}]^+$: 262.99, found m/z (%) 266.8 (10.3), 265.9 (9.1), 264.8 (62.3), 263.9 (14.9), 262.8 (M^+ , 100.0), 236.8 (8.0), 235.9 (2.1), 234.8 (13.3), 227.8 (2.7), 199.8 (6.9), 132.3 (2.5), 131.3 (3.9), 117.3 (3.5), 91.9 (5.0), 63.9 (8.3), 62.9 (9.5).




(E)-2-((3,5-dichlorobenzylidene)amino)phenol (4v): The general procedure was followed using (E)-2-((3,4-dichlorobenzylidene)amino)phenol (26.8 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4v** (22.2 mg, 84%) as a white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.12 (d, $J = 1.6$ Hz, 2H), 7.79-7.75 (m, 1H), 7.59-7.57 (m, 1H), 7.49-7.48 (m, 1H), 7.41-7.36 (m, 2H) ppm. $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 160.3, 150.7, 141.7, 135.7, 131.2, 129.8, 125.9, 125.7, 125.0, 120.4, 110.8 ppm. **MS (EI):** calculated for $[\text{M}^+] = [\text{C}_{13}\text{H}_7\text{Cl}_2\text{NO}]^+$: 262.99, found m/z (%) 266.


8 (9.8), 265.9 (8.5), 264.8 (59.9), 263.9 (15.0), 262.8 (M^+ , 100.0), 236.8 (9.1), 235.8 (2.2), 234.8 (14.0), 227.8 (3.0), 199.8 (5.6), 163.8 (2.9), 144.8 (2.0), 132.3 (3.2), 131.3 (4.6), 117.3 (3.0), 91.8 (5.1), 63.9 (8.6), 62.8 (9.7), 43.8 (3.3).




(E)-2-((3,5-dichlorobenzylidene)amino)phenol (4w): The general procedure was followed using (E)-2-((2,4,6-trimethylbenzylidene)amino)phenol (24.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **4w** (15.9 mg, 67%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 7.85-7.83 (m, 1H), 7.61-7.59 (m, 1H), 7.42-7.39 (m, 2H), 6.99 (m, 2H), 2.37 (m, 3H), 2.30 (s, 6H) ppm. **^{13}C NMR (100 MHz, $CDCl_3$):** δ 163.3, 150.6, 141.5, 140.3, 138.4, 128.6, 124.9, 124.2, 120.1, 110.6, 21.3, 20.3 ppm. **MS (EI):** calculated for [M^+] = [$C_{16}H_{15}NO$] $^+$: 237.12, found m/z (%) 238.0 (16.5), 236.9 (M^+ , 100.0), 235.9 (27.8), 221.9 (12.1), 220.9 (5.2), 219.9 (5.0), 207.9 (9.3), 206.9 (4.4), 146.9 (2.4), 129.9 (3.1), 118.8 (7.0), 114.9 (2.6), 90.9 (3.0).




2-cyclopropylbenzo[d]oxazole (4x): The general procedure was followed using (E)-2-((cyclopropylmethylene)amino)phenol (16.1 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 60:1) yielded **4x** (9.7mg, 61%) as a pale oil. **1H NMR (400 MHz, $CDCl_3$):** δ 7.61-7.59 (m, 1H), 7.43-7.41 (m, 1H), 7.29-7.22 (m, 2H), 2.24-2.17 (m, 1H), 1.29-1.25 (m, 2H), 1.19-1.14 (m, 2H) ppm. **^{13}C NMR (100 MHz, $CDCl_3$):** δ 168.6, 150.4, 141.5, 124.0, 123.9, 118.9, 110.0, 9.15 ppm. **MS (EI):** calculated for [M^+] = [$C_{10}H_9NO$] $^+$: 159.07, found m/z (%) 159.9 (9.3), 158.9 (M^+ , 100.0), 157.8 (82.4), 148.8 (8.5), 143.8 (8.7), 133.9 (5.0), 132.8 (59.4), 131.8 (3.5), 130.9 (5.6), 129.9 (14.62), 96.9 (4.7), 90.9 (6.3), 85.0 (6.3), 82.9 (6.0), 76.8 (6.4), 71.0 (7.5), 63.9 (8.1), 62.8 (11.4), 56.9 (9.9), 44.9 (7.8), 43.8 (61.2), 62.8 (11.4), 42.9 (10.8).




5-methyl-2-phenylbenzo[d]oxazole (4y): The general procedure was followed using (E)-2-(benzylideneamino)-4-methylphenol (21.1 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **4y** (18.8 mg, 90%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 8.26-8.23(m, 2H), 7.56-7.50 (m, 4H), 7.45 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 2.48 (s, 3H) ppm. **^{13}C NMR (100 MHz, $CDCl_3$):** δ 163.1, 148.9, 142.2, 134.4, 131.4, 128.8, 127.5, 127.3, 126.2, 119.9, 109.9, 21.5 ppm. **MS (EI):** calculated for [M^+] = [$C_{14}H_{11}NO$] $^+$: 209.08, found m/z (%) 209.9 (14.4), 208.9 (M^+ , 100.0), 207.8 (35.5), 179.9 (4.7), 105.9 (5.9), 104.8 (8.5), 104.0 (2.6), 77.9(13.3), 76.9 (11.0), 51.9 (3.5), 50.9 (5.0).




5-methoxy-2-phenylbenzo[d]oxazole (4z): The general procedure was followed using (E)-2-(benzylideneamino)-4-methoxyphenol (22.7 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 20:1) yielded **4z** (20.9 mg, 93%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.24-8.22 (m, 2H), 7.54-7.50 (m, 3H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.26 (d, *J* = 2.0 Hz, 1H), 6.96-6.93 (m, 1H), 3.87 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 163.8, 157.3, 145.4, 142.9, 131.4, 128.9, 127.4, 127.2, 113.7, 110.7, 102.8, 55.9 ppm. **MS (EI):** calculated for [M⁺] = [C₁₄H₁₁NO₂]⁺ : 225.08, found *m/z* (%) 225.9 (14.4), 224.9 (M⁺, 100.0), 210.9 (7.5), 209.8 (53.9), 181.9 (2.8), 106.8 (10.8), 78.8 (10.9), 52.9 (4.1), 50.9 (4.4), 43.8 (2.8).



5-fluoro-2-phenylbenzo[d]oxazole (5a): The general procedure was followed using (E)-2-(benzylideneamino)-4-fluorophenol (21.5 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **5a** (20.5 mg, 96%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.23 (d, *J* = 7.6 Hz, 2H), 7.58-7.50 (m, 3H), 7.47-7.45 (m, 1H), 7.11-7.07 (m, 1H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 164.7, 161.3, 158.9, 147.1, 142.9 (d, *J* = 13.0 Hz), 131.8, 128.9, 127.6, 126.8, 112.7 (d, *J* = 26.0 Hz), 110.8 (d, *J* = 22.0 Hz), 106.4 (d, *J* = 26.0 Hz) ppm. **MS (ESI):** calculated for [C₁₃H₈ClFNO]⁺: 214.07, found 214.02.




5-chloro-2-phenylbenzo[d]oxazole (5b): The general procedure was followed using (E)-2-(benzylideneamino)-4-chlorophenol (23.2 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5b** (21.4 mg, 93%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.23 (d, *J* = 8.0 Hz, 2H), 7.75 (t, *J* = 0.8 Hz, 1H), 7.58-7.48 (m, 4H), 7.33-7.31 (m, 1H). **¹³C NMR (100 MHz, CDCl₃):** δ 164.3, 149.3, 143.2, 131.9, 130.0, 128.9, 127.7, 126.6, 125.3, 119.9, 111.2. ppm. **MS (ESI):** calculated for [C₁₃H₉ClNO]⁺: 230.04, found 229.99.




5-bromo-2-phenylbenzo[d]oxazole (5c): The general procedure was followed using (E)-2-(benzylideneamino)-4-bromophenol (27.6 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5c** (21.7 mg, 79%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.26-8.24 (m, 2H), 7.92 (s, 1H), 7.60-7.52 (m, 3H), 7.48 (s, 2H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 164.2, 149.8, 143.8, 132.0, 129.0, 128.1, 127.8, 126.7, 123.0, 117.3, 111.8. ppm. **MS (EI):** calculated for [M⁺] = [C₁₃H₈BrNO]⁺ : 272.98, found *m/z* (%) 275.8 (12.4), 274.8 (95.3), 273.8 (16.1), 272.8 (M⁺, 100.0), 271.5 (3.6), 246.7 (10.7), 244.8 (10.1), 193.8 (4.9), 143.7 (3.9), 141.8 (4.4), 137.5


(5.6), 123.3 (3.7), 90.9 (6.2), 76.9 (7.5), 62.9 (17.5), 61.9 (4.6), 43.8 (12.7).




5-methyl-2-(p-tolyl)benzo[d]oxazole (5d): The general procedure was followed using (E)-4-methyl-2-((4-methylbenzylidene)amino)phenol (22.5 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5d** (20.1 mg, 90%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.14 (d, *J* = 8.0 Hz, 2H), 7.55 (s, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.14 (d, *J* = 8.4 Hz, 1H), 2.49 (s, 3H), 2.44 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 163.3, 148.9, 142.3, 141.9, 134.2, 129.6, 127.5, 125.9, 124.5, 119.7, 109.8, 21.6, 21.5 ppm. **HRMS (ESI):** calcd for C₁₅H₁₄NO [M+H]⁺ *m/z* 224.1070; found 224.1072.



5-methyl-2-(m-tolyl)benzo[d]oxazole (5e): The general procedure was followed using (E)-4-methyl-2-((3-methylbenzylidene)amino)phenol (22.8 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5e** (19.1 mg, 85%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.10 (s, 1H), 8.05 (d, *J* = 7.6 Hz, 1H), 7.57 (s, 1H), 7.47-7.40 (m, 2H), 7.35 (d, *J* = 7.6 Hz, 1H), 7.18-7.16 (m, 1H), 2.50 (s, 3H), 2.47 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 163.3, 148.9, 142.2, 138.7, 134.4, 132.3, 128.8, 128.1, 127.1, 126.2, 124.7, 119.8, 109.9, 21.5, 21.3 ppm. **HRMS (ESI):** calcd for C₁₅H₁₄NO [M+H]⁺ *m/z* 224.1070; found 224.1070.




5-methyl-2-(o-tolyl)benzo[d]oxazole (5f): The general procedure was followed using (E)-4-methyl-2-((2-methylbenzylidene)amino)phenol (22.2 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5f** (18.6 mg, 84%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.19-8.16 (m, 1H), 7.61 (s, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.44 (d, *J* = 1.6 Hz, 1H), 7.42-7.33 (m, 2H), 7.18 (dd, *J* = 1.2, 7.2 Hz, 1H), 2.82 (s, 3H), 2.51 (s, 3H). **¹³C NMR (100 MHz, CDCl₃):** δ 163.5, 148.5, 138.7, 134.1, 131.7, 130.7, 129.9, 126.4, 126.1, 126.0, 120.0, 109.8, 22.2, 21.5 ppm. **HRMS (ESI):** calcd for C₁₅H₁₄NO [M+H]⁺ *m/z* 224.1070; found 224.1069.




2-(4-chlorophenyl)-5-methylbenzo[d]oxazole (5g): The general procedure was followed using (E)-2-((4-chlorobenzylidene)amino)-4-methylphenol (24.6 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **5g** (22.2 mg, 91%) as a white solid. **¹H NMR (400 MHz, CDCl₃):** δ 8.18 (d, *J* = 8.8 Hz, 2H), 7.56 (s, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 8.4 Hz, 1H), 2.50 (s, 3H) ppm. **¹³C NMR (100 MHz, CDCl₃):** δ 162.1, 149.0, 142.1, 137.6, 134.6, 129.2, 128.8, 126.5, 125.7, 119.3, 110.0, 21.5 ppm. **HRMS (ESI):** calcd for C₁₄H₁₁ClNO


$[M+H]^+$ m/z 244.0529; found 244.0528.




2-(4-bromophenyl)-5-methylbenzo[d]oxazole (5h): The general procedure was followed using (E)-2-((4-bromobenzylidene)amino)-4-methylphenol (29.0 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **5h** (25.0 mg, 87%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 8.11 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.4 Hz, 2H), 7.56 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.19-7.17 (m, 1H), 2.50 (s, 3H) ppm. **^{13}C NMR (100 MHz, $CDCl_3$):** δ 162.2, 149.0, 142.2, 134.6, 132.2, 128.9, 126.5, 126.2, 126.0, 120.0, 110.0, 21.5 ppm. **HRMS (ESI):** calcd for $C_{14}H_{11}BrNO$ $[M+H]^+$ m/z 288.0024; found 288.0030.



2-(4-methoxyphenyl)-5-methoxybenzo[d]oxazole (5i): The general procedure was followed using (E)-4-methoxy-2-((4-methoxybenzylidene)amino)phenol (25.8 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 20:1) yielded **5i** (23.2 mg, 91%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 8.17 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 8.8 Hz, 1H), 7.27-7.24 (m, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.93-6.90 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H) ppm. **^{13}C NMR (100 MHz, $CDCl_3$):** δ 163.9, 162.2, 157.2, 145.3, 143.0, 129.2, 119.7, 114.3, 112.9, 110.5, 55.9, 55.4 ppm. **HRMS (ESI):** calcd for $C_{15}H_{14}NO_3$ $[M+H]^+$ m/z 256.0968; found 256.0967.




5-fluoro-2-(4-fluorophenyl)benzo[d]oxazole (5j): The general procedure was followed using (E)-4-fluoro-2-((4-fluorobenzylidene)amino)phenol (23.3 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5j** (20.8 mg, 90%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 8.26-8.22 (m, 2H), 7.52-7.49 (m, 1H), 7.45-7.42 (m, 1H), 7.26-7.11 (m, 3H), 7.11-7.06 (m, 1H). **^{13}C NMR (100 MHz, $CDCl_3$):** δ 166.2, 163.8 (d, J = 16.0 Hz), 161.4, 159.0, 147.1, 142.9 (d, J = 13.0 Hz), 130.0 (d, J = 9.0 Hz), 123.2, 116.3 (d, J = 22.0 Hz), 112.7 (d, J = 26.0 Hz), 110.9 (d, J = 10.0 Hz), 106.4 (d, J = 25.0 Hz). **HRMS (ESI):** calcd for $C_{13}H_8F_2NO$ $[M+H]^+$ m/z 232.0568; found 232.0571.




5-chloro-2-(4-chlorophenyl)benzo[d]oxazole (5k): The general procedure was followed using (E)-4-chloro-2-((4-chlorobenzylidene)amino)phenol (26.6 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5k** (23.5 mg, 89%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 8.20-8.16 (m, 2H), 7.75 (d, J = 1.6 Hz, 1H), 7.54-7.50 (m, 3H), 7.36-7.33 (m, 1H). **^{13}C NMR (100 MHz, $CDCl_3$):** δ 163.3, 149.3, 143.1, 138.2, 130.2, 129.3, 128.9, 125.6, 125.1, 120.0, 111.3

ppm. **HRMS (ESI):** calcd for $C_{13}H_8C_{12}NO$ $[M+H]^+$ m/z 263.9977; found 263.9989.



2-(4-bromophenyl)-5-chlorobenzo[d]oxazole (5l): The general procedure was followed using (E)-2-((4-bromobenzylidene)amino)-4-chlorophenol (31.1 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 30:1) yielded **5l** (26.2 mg, 85%) as a white solid. **1H NMR** (400 MHz, $CDCl_3$): δ 8.12-8.08 (m, 2H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.69-7.67 (m, 2H), 7.50 (d, $J = 8.8$, 1H), 7.36-7.33 (m, 1H). **^{13}C NMR** (100 MHz, $CDCl_3$): δ 163.4, 149.3, 143.1, 132.3, 130.2, 129.1, 126.7, 125.7, 125.6, 120.0, 111.4 ppm. **HRMS (ESI):** calcd for $C_{13}H_8BrClNO$ $[M+H]^+$ m/z 307.9472; found 307.9475.





5-bromo-2-(4-bromophenyl)benzo[d]oxazole (5m): The general procedure was followed using (E)-4-bromo-2-((4-bromobenzylidene)amino)phenol (35.5 mg, 0.10 mmol). Purification by column chromatography (PE→PE/EtOAc = 40:1) yielded **5m** (28.8 mg, 81%) as a white solid. **1H NMR (400 MHz, $CDCl_3$):** δ 8.11 (d, $J = 8.4$ Hz, 2H), 7.91 (s, 1H), 7.69 (d, $J = 8.8$ Hz, 2H), 7.51-7.46 (m, 2H) ppm. **^{13}C NMR (100 MHz, $CDCl_3$):** 163.3, 149.7, 145.3, 143.6, 132.3, 129.1, 128.4, 126.8, 125.5, 123.1, 117.5, 111.9 ppm. **HRMS (ESI):** calcd for $C_{13}H_8Br_2NO$ $[M+H]^+$ m/z 351.8968; found 351.8972.



12. REFERENCES



- [1] D. S. Bose, L. Fatima, H. B. Mereyala, *J. Org. Chem.*, 2003, **68**, 587.
- [2] N. N. Karade, S. V. Gampawar, N. P. Tale, S. B. Kedar, *J. Heterocyclic Chem.*, 2010, **47**, 740.
- [3] B.-C. Chen, M.S. Bednarz, H. Zhang, P. Guo, M. J. J. A. Robl, S. A. Biller, J. E. Sundeen, B. Balasubramanian, J. C. Barrish, *J Label Compd Radiopharm*, 2006, **49**, 311.
- [4] M. Watanabe, H. Koike, T. Ishiba, T. Okada, S. Seo, K. Hirai, *Bioorg. Med. Chem.*, 1997, **5**, 437.
- [5] (a) J. J. V. Eynde, N. Audiart, V. Canonne, S. Michel, Y. V. Haverbeke, *Heterocycles*, 1997, **45**, 1967. (b) B. Han, R.-F. Han, Y.-W. Ren, X.-Y. Duan, Y.-C. Xu, W. Zhang, *Tetrahedron*, 2011, **67**, 5615.
- [6] L. E. Overman, D. A. Watson, *J. Org. Chem.*, 2006, **71**, 2587.
- [7] (a) Y.-H. Cho, C.-Y. Lee, D.-C. Ha, C.-H. Cheon, *Adv. Synth. Catal.*, 2012, **354**, 2992. (b) Y.-H. Cho, C.-Y. Lee, C.-H. Cheon, *Tetrahedron*, 2013, **69**, 6565.



13. NMR SPECTRA



13.1 NMR Spectra Of 2-Substituted Dihydropyrimidines 1a-1x.

































































































13.2 NMR Spectra Of 2-Substituted Pyrimidines 2a-2x.























































































13.3 NMR Spectra Of 2-Substituted Benzoxazoles 4a-5m.

